MedTrace Logo

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

NCT07448480 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-03-04

No results posted yet for this study

Summary

GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas. The study includes patients with molecularly confirmed diagnoses according to the World Health Organization (WHO) 2021 classification of Central Nervous System (CNS) tumors: glioblastomas (IDH-wildtype, WHO grade 4), astrocytomas (IDH-mutant, WHO grade 3-4), and pleomorphic xanthoastrocytomas (WHO grade 2-3).

Conditions

  • Recurrent Malignant Glioma
  • Glioblastoma
  • Anaplastic Astrocytoma
  • Pleomorphic Xanthoastrocytoma

Interventions

DRUG

Bevacizumab-Containing Regimens

Patients receiving any line of therapy that includes bevacizumab (alone or in combination with other agents such as temozolomide, irinotecan, lomustine, carboplatin, etc.)

DRUG

Non-Bevacizumab Regimens

Patients receiving conventional chemotherapy without bevacizumab (including temozolomide monotherapy, PCV regimen, nitrosoureas, platinum compounds, etc.)

DRUG

BRAF ± MEK Targeted Therapy

Patients harboring BRAF mutations receiving targeted therapy with BRAF inhibitors (dabrafenib, vemurafenib) alone or in combination with MEK inhibitors (trametinib, cobimetinib), with or without concomitant chemotherapy

Sponsors & Collaborators

  • Blokhin's Russian Cancer Research Center

    lead OTHER

Principal Investigators

  • David Naskhletashvili, MD, PhD · N.N. Blokhin National Medical Research Center of Oncology

  • David Khalafyan, MD · N.N. Blokhin National Medical Research Center of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-10-01
Completion
2027-10-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07448480 on ClinicalTrials.gov